Q-omics provides the consensus-scored FAM228A profile across patient tissues and cancer cell-line models. FAM228A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, FAM228A is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, FAM228A RNA expression shows 15,845 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, BRCA, and UVM as cancer lineages where FAM228A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM228A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM228A survival associations across molecular data types. FAM228A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM228A RNA expression–survival associations across cancer types. High FAM228A expression shows unfavorable associations in OV, UVM and UCEC, but favorable associations in LUAD, HNSC and PAAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for FAM228A RNA expression.
This table summarizes FAM228A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM228A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM228A shows lower tumor expression in BRCA, KICH, LUSC, UCEC, THCA and BLCA. The BRCA box plot shows higher FAM228A RNA expression in normal versus tumor tissue (log2 FC = −0.763, t-test p < 0.001).
This table shows molecular features associated with FAM228A in patient tissues and cancer cell lines. In patient samples, FAM228A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM228A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
